Biomarkers for Alzheimer's disease therapeutic trials by Hampel, H, Wilcock, G, Andrieu, S, Aisen, P, Blennow, K, Broich, K, Carrillo, M, Fox, N, Frisoni, G, Isaac, M, Lovestone, S, Nordberg, A, Prvulovic, D, Sampaio, C, Scheltens, P, Weiner, M, Winblad, B, Coley, N, Vellas, B

Biomarkers for Alzheimer's disease therapeutic trials. by Hampel, H, Wilcock, G, Andrieu, S, Aisen, P, Blennow, K, Broich, K, Carrillo, M, Fox, N, Frisoni, G, Isaac, M, Lovestone, S, Nordberg, A, Prvulovic, D, Sampaio, C, Scheltens, P, Weiner, M, Winblad, B, Coley, N, Vellas, B

Design of clinical trials in bipolar disorders by Tohen, M, Bowden, C, Berk, M, Berlanga, C, Andrade, C, Broich, K, Calabrese, JR, Frank, E, Geddes, J, Goodwin, G, Ha, K, Hirschfeld, B, Kanba, S, Keck, P, Lafer, B, Licht, R, Nierenberg, A, Nolen, W, Suppes, T, Tamayo, J, Vieta, E, Yatham, L, Carlson, B

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. by Vellas, B, Carrillo, M, Sampaio, C, Brashear, H, Siemers, E, Hampel, H, Schneider, L, Weiner, M, Doody, R, Khachaturian, Z, Cedarbaum, J, Grundman, M, Broich, K, Giacobini, E, Dubois, B, Sperling, R, Wilcock, G, Fox, N, Scheltens, P, Touchon, J, Hendrix, S, Andrieu, S, Aisen, P

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. by Burns, A, O'Brien, J, Auriacombe, S, Ballard, C, Broich, K, Bullock, R, Feldman, H, Ford, G, Knapp, M, McCaddon, A, Iliffe, S, Jacova, C, Jones, R, Lennon, S, McKeith, I, Orgogozo, J, Purandare, N, Richardson, M, Ritchie, C, Thomas, A, Warner, J, Wilcock, G, Wilkinson, D